Cardiovascular disease: An economical perspective

Current Pharmaceutical Design

Volumn 15, Issue 10, 2009, Pages 1142-1156

  Lazzini, Arianna ^a   Lazzini, S ^b  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^b UNIVERSITY OF PISA   (Italy)

Author keywords

Cardiovascular risk assessment; Disease management; Organizational change; Patient oriented model; Prevention costs

Indexed keywords

ABSENTEEISM; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAUSE OF DEATH; CEREBROVASCULAR DISEASE; DOCTOR PATIENT RELATION; ECONOMIC EVALUATION; EVIDENCE BASED MEDICINE; HEALTH CARE COST; HEALTH CARE DELIVERY; HEALTH CARE SYSTEM; HEALTH PROGRAM; HEALTH SERVICE; HUMAN; ISCHEMIC HEART DISEASE; ITALY; LIFESTYLE; PRACTICE GUIDELINE; PRIMARY PREVENTION; PRIORITY JOURNAL; PRODUCTIVITY; QUALITY OF LIFE; REVIEW; RISK REDUCTION; SOCIAL ASPECT; WORLD HEALTH ORGANIZATION;

CARDIOVASCULAR DISEASES; COST OF ILLNESS; DELIVERY OF HEALTH CARE; HUMANS; ITALY; MODELS, ORGANIZATIONAL; NATIONAL HEALTH PROGRAMS;

EID: 65649134320     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161209787846883     Document Type: Review

References (31)

1. World Health Organization, Preventing Chronic Diseases: A Vital Investment, Geneva, Switzerland, 2005
2. Leal J, Luengo-Fernàndez R, Gray A, Petersen S, Rayner M. Economic burden of cardiovascular diseases in the enlarged European Union. Eur Heart J 2006; 27:1521-22.
3. Abegunde DO, Mathers CD, Adam T, Strong K. The burden and cost of chronic disease in low-income and middle income countries. Lancet 2007; 370: 1929-38.
4. Porter ME, Teisberg EO, Redefining Health Care: Creating Value-Based Competition on Results, Harvard Business School Press 2006.
5. Grundy SM, Pasternak R, Greenland P, Smith S, Fuster V. Assessment of Cardiovascular Risk by Use of Multiple-Risk-Factor Assessment Equations. Circulation 1999; 100(13): 1481-92.
6. Wood D, De Backer G, Faergeman O, Graham I, Mancia G, Pyr̈älä K. Prevention of coronary heart disease in clinical practice: Recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention. Atherosclerosis 1998; 140(2): 199-270.
7. Wong ND, Black HR, Gardin JM. Preventive Cardiology. McGraw-Hill Professional 1999.
8. Christiaens T. Cardiovascular risk tables, BMJ 2008; 336:1445-46.
9. Leone A. Relationship Between Cigarette Smoking and Other Coronary Risk Factors in Atherosclerosis: Risk of Cardiovascular Disease and Preventive Measures, Curr Pharm Des 2003; 9(29): 2417-23.
10. Fiore MC, Smith SS, Jorenby DE, Baker TB. The effectiveness of the nicotine patch for smoking cessation. A meta-analysis. J Am Med Assoc 1994; 271(24): 1940-47.
11. Burke LE, Dunbar-Jacob J. Adherence to medication, diet, and activity recommendations: From assessment to maintenance. J Cardiovasc Nurs 1995; 9(2): 62-79.
12. Burke LE, Dunbar-Jacob JM, Hill MN. Compliance with cardiovascular disease prevention strategies: A review of the research. Annal Behav Med 1997; 19(3): 239-263.
13. Wagner E.H., Diversifying the options for interacting with patients. Postgrad Med J 2007; 83.
14. Wagner EH, Davis C, Schaefer J, Von Korff M, Austin B. A survey of leading chronic disease management programs: are they consistent with the literature? Manag Care Q 1999; 7: 56-66.
15. Jill JG, Montgomery SB, Emmons CA, Kessler RC, Ostrow DG, Wortman CB, et al. Magnitude and determinants of behavioral risk reduction: Longitudinal analysis of a cohort at risk, for AIDS. Psychol Health 1987; 1(1).
16. Koszsegi B. Emotional agency. Q J Econ 2006; 121(1): 121-155.
17. Caplin A. Fear as a policy instrument, in Time and Decision, Baumeister R, Loewenstein G, Read D, Eds. New York, Russell Sage 2003.
18. Cutler DM. Behavioral health interventions: what works and why?, in R. Bulatao, N. Anderson, eds., Understanding Racial and Ethnic Differences in Health in Late Life: A Research Agenda, Washington, D.C. National Academies Press 2004.
19. Anselmi L. Il processo di trasformazione delta pubblica amministrazione, Il percorso aziendale, Torin, Giappichelli 1995.
20. Del Bene L. Criteri e strumenti per il controllo gestionale nelle aziende sanitarie, Milan, Giuffrè, 2000.
21. Del Vecchio M. Le aziende sanitarie tra specializzazione organizzativa, deintegrazione istituzionale e relazioni di rete pubblica, in Anessi Pessina, Cantù eds. L'aziendalizzazione della sanità in Italia - OASI Report 2003, Milan, Egea 2003.
22. Bartlett W, Le Grand J., Quasi market and social policy, London, MacMillan 2003.
23. Marinò L. Dinamiche competitive ed equilibrio economico nelle aziende sanitarie Milan, Giuffrè 2001.
24. Cicchetti A, Mascia D, Organizzare le reti in sanità: teoria, metodi e strumenti di social network analysis. Mecosan 2007; 61.
25. Roccato E, Dipartimento di prevenzione:ipotesi organizzativa nella azienda sanitaria locale di Firenze, Mecosan1995; 15.
26. Grandori A., Knowledge governance mechanisms and the theory of the firms. Working paper, University of Modena e Reggio Emilia 2003.
27. Risk charts are based on global absolute risk classes calculated for categories of risk factors and take into account ranges of values of total serum cholesterol and blood pressure. The individual risk score, instead, uses continuous values of total serum cholesterol, serum HDL cholesterol, age and blood pressure and provide a more precise estimation of cardiovascular risk. Source: www.cuore.iss.it/sopra/ calc-rischio en.asp
28. The Istituto Superiore di Sanità (ISS) is the leading technical and scientific public body of the Italian National Health Service. Its activities include research, control, training and consultation in the interest of public health protection. Source: www.iss.it/chis/ ?lang=2
29. De Rijdt T, Willems L, Simoens S. Economic effects of clinical pharmacy interventions: a literature review. Am J Health Syst Pharm 2008; 65(12): 1161-72.
30. Huston SA, Hawkins D. Pharmacoeconomics of anticoagulants in acute coronary syndrome and percutaneous coronary intervention. Curr Pharm Des 2008; 14(12): 1197-204.
31. Landini L, Leone A. Modifying cardiovascular risk factors: novel cardiovascular targets for treatment by noninvasive imaging techniques. Curr Pharm Des 2008; 14(18): 1743-4.